• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高效抗丙型肝炎治疗:来自艾滋病治疗的七点经验教训。

Highly active anti-hepatitis C therapy: seven lessons from HIV.

作者信息

Thomas David L

机构信息

Johns Hopkins School of Medicine, Baltimore, MD, USA.

出版信息

Antivir Ther. 2012;17(6 Pt B):1183-8. doi: 10.3851/IMP2429. Epub 2012 Oct 5.

DOI:10.3851/IMP2429
PMID:23186629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3715614/
Abstract

The HCV direct-acting antiviral treatment era is underway. Although there are some important differences, it is likely that the experience with HCV will be similar in many respects to what already occurred with HIV. This paper considers seven important lessons learned with HIV and the degree to which they should be anticipated with HCV.

摘要

丙型肝炎病毒(HCV)直接抗病毒治疗时代已经开启。尽管存在一些重要差异,但HCV的治疗经验在许多方面可能与HIV已有的情况相似。本文探讨了从HIV治疗中学到的七个重要经验教训,以及在HCV治疗中预期会出现这些经验教训的程度。

相似文献

1
Highly active anti-hepatitis C therapy: seven lessons from HIV.高效抗丙型肝炎治疗:来自艾滋病治疗的七点经验教训。
Antivir Ther. 2012;17(6 Pt B):1183-8. doi: 10.3851/IMP2429. Epub 2012 Oct 5.
2
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.丙型肝炎直接抗病毒治疗时代的临床实验室检测
Clin Microbiol Rev. 2017 Jan;30(1):23-42. doi: 10.1128/CMR.00037-16. Epub 2016 Oct 19.
3
Are we nearing the end in the fight against hepatitis C?我们是否正在接近丙型肝炎防治工作的尾声?
Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):499-500. doi: 10.1080/17474124.2017.1309287. Epub 2017 Mar 28.
4
Antiviral resistance and specifically targeted therapy for HCV (STAT-C).丙型肝炎病毒的抗病毒耐药性及特异性靶向治疗(STAT-C)
J Viral Hepat. 2009 Jun;16(6):377-87. doi: 10.1111/j.1365-2893.2009.01124.x.
5
The remaining challenges of HCV treatment in the direct-acting antivirals era.直接作用抗病毒药物时代丙型肝炎病毒治疗的剩余挑战。
J Gastroenterol Hepatol. 2019 Nov;34(11):1891-1892. doi: 10.1111/jgh.14916.
6
Direct-acting antiviral agents for the treatment of HCV.用于治疗丙型肝炎病毒的直接抗病毒药物。
Antivir Ther. 2012;17(6 Pt B):1105-7. doi: 10.3851/IMP2422. Epub 2012 Oct 5.
7
Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?直接作用抗病毒药物治疗慢性丙型肝炎的未来:耐药性重要吗?
Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x.
8
Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?在由瑞安·怀特基金资助的艾滋病诊所治疗丙型肝炎:在无干扰素直接抗病毒时代,治疗接受率是否有所提高?
AIDS Patient Care STDS. 2016 Feb;30(2):51-5. doi: 10.1089/apc.2015.0222. Epub 2016 Jan 8.
9
Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?直接作用抗病毒药物治疗 HIV 感染者的丙型肝炎病毒感染 - “迈向根治”?
J Infect. 2017 Sep;75(3):234-241. doi: 10.1016/j.jinf.2017.05.008. Epub 2017 Jun 2.
10
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.直接作用抗病毒药物治疗慢性丙型肝炎:优势与挑战。
Int J Med Sci. 2020 Mar 15;17(7):892-902. doi: 10.7150/ijms.43079. eCollection 2020.

本文引用的文献

1
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.1999 年至 2007 年期间,美国因病毒性肝炎导致的死亡率负担不断增加。
Ann Intern Med. 2012 Feb 21;156(4):271-8. doi: 10.7326/0003-4819-156-4-201202210-00004.
2
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.美国初级保健环境中基于出生队列的丙型肝炎抗体筛查的成本效益分析。
Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.
3
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells.在接受抗逆转录病毒治疗的 HIV 患者中,CD4+T 细胞缺陷与 CD4+T 细胞中干扰素刺激基因的表达增加有关。
J Infect Dis. 2011 Dec 15;204(12):1927-35. doi: 10.1093/infdis/jir659. Epub 2011 Oct 17.
4
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).尽管存在肝硬化,但经肝内内毒素梯度仍然存在,经颈静脉肝内门体分流术 (TIPS) 后其减轻。
BMC Gastroenterol. 2011 Oct 6;11:107. doi: 10.1186/1471-230X-11-107.
5
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.分析替拉瑞韦或博赛泼维治疗后丙型肝炎病毒 NS3 蛋白酶内耐药突变的长期持续存在。
J Clin Virol. 2011 Dec;52(4):321-7. doi: 10.1016/j.jcv.2011.08.015. Epub 2011 Sep 15.
6
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.1型慢性丙型肝炎病毒感染治疗的最新进展:美国肝病研究协会2011年实践指南
Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
7
Outcomes of treatment for hepatitis C virus infection by primary care providers.基层医疗服务提供者治疗丙型肝炎病毒感染的结果。
N Engl J Med. 2011 Jun 9;364(23):2199-207. doi: 10.1056/NEJMoa1009370. Epub 2011 Jun 1.
8
Curing hepatitis C with pills: a step toward global control.用药物治愈丙型肝炎:迈向全球控制的一步。
Lancet. 2010 Oct 30;376(9751):1441-2. doi: 10.1016/S0140-6736(10)61497-3. Epub 2010 Oct 14.
9
Age at cancer diagnosis among persons with AIDS in the United States.美国艾滋病患者的癌症诊断年龄。
Ann Intern Med. 2010 Oct 5;153(7):452-60. doi: 10.7326/0003-4819-153-7-201010050-00008.
10
Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.CD4+T 细胞计数低是 HIV 门诊研究中心血管疾病事件的一个风险因素。
Clin Infect Dis. 2010 Aug 15;51(4):435-47. doi: 10.1086/655144.